erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the
.
the financial times and its journalism are subject to a self-regulation regime under the ft editorial code of practice:
.
stephen silberstein, md, director, jefferson university headache center.
.
.
. therapy, hdl particle size got smaller (not a good thing) and the hdl worked less effectively to remove cholesterol from the body," mehta said.
.
.
.
.
.